PET/CT: C-reactive protein could be a precursor to cardiovascular disease

FDG uptake rose substantially in PET/CT scans of patients with higher levels of C-reative protein in their carotid arteries, pinpointing a potential biomarker for cardiovascular disease, according to an article published online Oct. 31 in the Journal of Nuclear Medicine.

Tae Soo Noh, a researcher from the department of nuclear medicine at Samsung Medical Center and Sungkyunkwan University School of Medicine in Seoul, Korea, and colleagues assessed the association between F-18 FDG uptake in carotid arteries, a

high-sensitivity C-reactive protein and patient risk using the standard Framingham risk score (FRS), which calculated the estimated 10-year risk of developing cardiovascular disease in a group of 1,181 adults without symptoms of heart disease.

“High carotid F-18 FDG uptake in asymptomatic adults is associated with increased clinical risk factors and greater FRS,” wrote the authors. “Furthermore, carotid F-18 FDG uptake appears to reflect aspects of atherosclerotic inflammation distinct from [high-sensitivity C-reactive protein] level and may offer incremental risk–related information.”

Researchers found that FRS scores swelled from about 11.5 percent risk of developing cardiovascular disease to 14.8 percent in patients with maximum target-to-background ratios greater or equal to 1.7, indicating a strong link between FDG uptake, carotid C-reative protein levels and risk of disease.

Additional studies need to be conducted to gain a better understanding of the full impact of C-reative protein levels in the development of atherosclerosis.

Around the web

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.